News MSD takes a $400m bite of SciBrunch's KRAS drug MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.
News Novavax critic Shah Capital ends its activism campaign Shah Capital has ended attempts to exert influence over vaccine firm Novavax, bringing more than years of pressure on management to an end.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
